3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
4
Waldenstrom Macroglobulinemia
1
Mature B-cell Neoplasms
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, B-Cell
1
Hematologic Neoplasms
1
Interventions
venetoclax
6
ibrutinib
4
pirtobrutinib
2
Sirolimus
2
Rituximab
2
Mycophenolic Acid
2
Cyclosporine
2
Cyclophosphamide
2
zanubrutinib
1
pembrolizumab
1
loncastuximab tesirine
1
fludarabine phosphate
1
carfilzomib
1
acalabrutinib
1
Whole-Body Irradiation
1
Tacrolimus
1
Specimen Handling
1
Rifaximin
1
Peripheral Blood Stem Cell Transplantation
1
Methotrexate
1
Melphalan
1
Magnetic Resonance Spectroscopy
1
Etoposide
1
Dexamethasone
1
Cyclosporins
1
Calcium Dobesilate
1
CT-P10
1
Busulfan
1
Biopsy
1
ARQ531
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Waldenstrom Macroglobulinemia
×
ARQ531
×
30 days
×
Clear all
NCT04728893
2026-05-26
MK-1026-003
Merck Sharp & Dohme LLC
Phase 2
Recruiting
490 enrolled